NO301577B1 - Fremgangsmåte for fremstilling av en stabil vaksineblanding og fremgangsmåte for stabilisering av interleukin i en vaksineblanding - Google Patents

Fremgangsmåte for fremstilling av en stabil vaksineblanding og fremgangsmåte for stabilisering av interleukin i en vaksineblanding Download PDF

Info

Publication number: NO301577B1
Authority: NO; Norway
Prior art keywords: interleukin; antigen; bacterial; rhil; alum
Prior art date: 1989-07-14

Application number

NO920161A

Other languages

English (en)

Norwegian (no)

Other versions

NO920161L (no

NO920161D0 (no

Inventor

Subramonia Pillai

Garvin Bixler

Original Assignee

American Cyanamid Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-07-14

Filing date

1992-01-13

Publication date

1997-11-17

1992-01-13 Application filed by American Cyanamid Co filed Critical American Cyanamid Co

1992-01-13 Publication of NO920161D0 publication Critical patent/NO920161D0/no

1992-03-05 Publication of NO920161L publication Critical patent/NO920161L/no

1997-11-17 Publication of NO301577B1 publication Critical patent/NO301577B1/no

Links

229960005486 vaccine Drugs 0.000 title claims abstract description 40
102000015696 Interleukins Human genes 0.000 title claims abstract description 38
108010063738 Interleukins Proteins 0.000 title claims abstract description 38
238000000034 method Methods 0.000 title claims description 17
230000000087 stabilizing effect Effects 0.000 title claims description 4
239000000427 antigen Substances 0.000 claims abstract description 59
102000036639 antigens Human genes 0.000 claims abstract description 59
108091007433 antigens Proteins 0.000 claims abstract description 59
229940037003 alum Drugs 0.000 claims abstract description 38
239000000203 mixture Substances 0.000 claims abstract description 33
239000002671 adjuvant Substances 0.000 claims abstract description 18
239000003755 preservative agent Substances 0.000 claims abstract description 6
230000002335 preservative effect Effects 0.000 claims abstract description 6
230000001580 bacterial effect Effects 0.000 claims description 12
241000725643 Respiratory syncytial virus Species 0.000 claims description 11
229920000642 polymer Polymers 0.000 claims description 10
102000003886 Glycoproteins Human genes 0.000 claims description 7
108090000288 Glycoproteins Proteins 0.000 claims description 7
108010002350 Interleukin-2 Proteins 0.000 claims description 7
102000000588 Interleukin-2 Human genes 0.000 claims description 7
102000000646 Interleukin-3 Human genes 0.000 claims description 7
108010002386 Interleukin-3 Proteins 0.000 claims description 7
241000700605 Viruses Species 0.000 claims description 7
102000004196 processed proteins & peptides Human genes 0.000 claims description 7
108090000765 processed proteins & peptides Proteins 0.000 claims description 7
108090000623 proteins and genes Proteins 0.000 claims description 7
108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims description 6
241000606768 Haemophilus influenzae Species 0.000 claims description 6
241000588650 Neisseria meningitidis Species 0.000 claims description 6
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 6
229940047650 haemophilus influenzae Drugs 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
102000004169 proteins and genes Human genes 0.000 claims description 6
102000000589 Interleukin-1 Human genes 0.000 claims description 5
108010002352 Interleukin-1 Proteins 0.000 claims description 5
102000004388 Interleukin-4 Human genes 0.000 claims description 5
108090000978 Interleukin-4 Proteins 0.000 claims description 5
102000000743 Interleukin-5 Human genes 0.000 claims description 5
108010002616 Interleukin-5 Proteins 0.000 claims description 5
102000004889 Interleukin-6 Human genes 0.000 claims description 5
108090001005 Interleukin-6 Proteins 0.000 claims description 5
102000000704 Interleukin-7 Human genes 0.000 claims description 5
108010002586 Interleukin-7 Proteins 0.000 claims description 5
108010052285 Membrane Proteins Proteins 0.000 claims description 5
241000702670 Rotavirus Species 0.000 claims description 5
241000193996 Streptococcus pyogenes Species 0.000 claims description 5
229940076264 interleukin-3 Drugs 0.000 claims description 5
229940028885 interleukin-4 Drugs 0.000 claims description 5
229940100602 interleukin-5 Drugs 0.000 claims description 5
229940100601 interleukin-6 Drugs 0.000 claims description 5
229940100994 interleukin-7 Drugs 0.000 claims description 5
239000000126 substance Substances 0.000 claims description 5
241000588747 Klebsiella pneumoniae Species 0.000 claims description 4
241000588655 Moraxella catarrhalis Species 0.000 claims description 4
241000588652 Neisseria gonorrhoeae Species 0.000 claims description 4
241000589517 Pseudomonas aeruginosa Species 0.000 claims description 4
241000191967 Staphylococcus aureus Species 0.000 claims description 4
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 4
239000007900 aqueous suspension Substances 0.000 claims description 4
239000002775 capsule Substances 0.000 claims description 4
235000014633 carbohydrates Nutrition 0.000 claims description 4
150000001720 carbohydrates Chemical class 0.000 claims description 4
239000012634 fragment Substances 0.000 claims description 4
229920001184 polypeptide Polymers 0.000 claims description 4
230000003612 virological effect Effects 0.000 claims description 4
241000894006 Bacteria Species 0.000 claims description 3
241000233866 Fungi Species 0.000 claims description 3
241000725303 Human immunodeficiency virus Species 0.000 claims description 3
206010028980 Neoplasm Diseases 0.000 claims description 3
101710116435 Outer membrane protein Proteins 0.000 claims description 3
229910019142 PO4 Inorganic materials 0.000 claims description 3
241000193998 Streptococcus pneumoniae Species 0.000 claims description 3
244000052616 bacterial pathogen Species 0.000 claims description 3
201000011510 cancer Diseases 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
208000002672 hepatitis B Diseases 0.000 claims description 3
239000000463 material Substances 0.000 claims description 3
244000045947 parasite Species 0.000 claims description 3
238000003860 storage Methods 0.000 claims description 3
229940031000 streptococcus pneumoniae Drugs 0.000 claims description 3
231100000699 Bacterial toxin Toxicity 0.000 claims description 2
241000588832 Bordetella pertussis Species 0.000 claims description 2
241000193449 Clostridium tetani Species 0.000 claims description 2
102000016607 Diphtheria Toxin Human genes 0.000 claims description 2
108010053187 Diphtheria Toxin Proteins 0.000 claims description 2
241000588724 Escherichia coli Species 0.000 claims description 2
108091006027 G proteins Proteins 0.000 claims description 2
102000030782 GTP binding Human genes 0.000 claims description 2
108091000058 GTP-Binding Proteins 0.000 claims description 2
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 2
101710085938 Matrix protein Proteins 0.000 claims description 2
102000018697 Membrane Proteins Human genes 0.000 claims description 2
101710127721 Membrane protein Proteins 0.000 claims description 2
201000005702 Pertussis Diseases 0.000 claims description 2
206010043376 Tetanus Diseases 0.000 claims description 2
241000607626 Vibrio cholerae Species 0.000 claims description 2
239000000688 bacterial toxin Substances 0.000 claims description 2
206010013023 diphtheria Diseases 0.000 claims description 2
231100000590 oncogenic Toxicity 0.000 claims description 2
230000002246 oncogenic effect Effects 0.000 claims description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
239000010452 phosphate Substances 0.000 claims description 2
229940118696 vibrio cholerae Drugs 0.000 claims description 2
102000004890 Interleukin-8 Human genes 0.000 claims 1
108090001007 Interleukin-8 Proteins 0.000 claims 1
102000000585 Interleukin-9 Human genes 0.000 claims 1
108010002335 Interleukin-9 Proteins 0.000 claims 1
101710141454 Nucleoprotein Proteins 0.000 claims 1
230000028993 immune response Effects 0.000 abstract description 15
229940047122 interleukins Drugs 0.000 abstract description 12
230000001681 protective effect Effects 0.000 abstract description 8
229910052500 inorganic mineral Inorganic materials 0.000 abstract description 7
239000011707 mineral Substances 0.000 abstract description 7
239000000725 suspension Substances 0.000 abstract description 4
230000004071 biological effect Effects 0.000 abstract description 2
241000699666 Mus <mouse, genus> Species 0.000 description 11
239000000546 pharmaceutical excipient Substances 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 7
210000004027 cell Anatomy 0.000 description 7
238000002255 vaccination Methods 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
241000699670 Mus sp. Species 0.000 description 5
230000005875 antibody response Effects 0.000 description 5
230000000694 effects Effects 0.000 description 5
239000000839 emulsion Substances 0.000 description 5
230000000240 adjuvant effect Effects 0.000 description 4
230000003053 immunization Effects 0.000 description 4
238000002649 immunization Methods 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
230000004044 response Effects 0.000 description 4
230000004936 stimulating effect Effects 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
-1 ethanol polyols Chemical class 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000001717 pathogenic effect Effects 0.000 description 3
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
230000005867 T cell response Effects 0.000 description 2
239000002253 acid Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
230000002519 immonomodulatory effect Effects 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
238000005462 in vivo assay Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
201000004792 malaria Diseases 0.000 description 2
244000052769 pathogen Species 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
229920005862 polyol Polymers 0.000 description 2
239000000047 product Substances 0.000 description 2
229940023143 protein vaccine Drugs 0.000 description 2
230000009467 reduction Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
ITFICYZHWXDVMU-IPTZIORSSA-N (2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-2-[[(2S,3R)-2-[[(2S,3S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-amino-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-oxopentanoyl]amino]pentanedioic acid Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(=O)O)N ITFICYZHWXDVMU-IPTZIORSSA-N 0.000 description 1
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
LYFYWXLKKQIOKO-UHFFFAOYSA-N 3,3-diaminopentan-1-ol Chemical compound CCC(N)(N)CCO LYFYWXLKKQIOKO-UHFFFAOYSA-N 0.000 description 1
AWIGZBIWTRYADH-UHFFFAOYSA-N 3-methoxynonadecane-1,2,3-triol Chemical compound CCCCCCCCCCCCCCCCC(O)(OC)C(O)CO AWIGZBIWTRYADH-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
241000711573 Coronaviridae Species 0.000 description 1
201000007336 Cryptococcosis Diseases 0.000 description 1
241000221204 Cryptococcus neoformans Species 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
238000011765 DBA/2 mouse Methods 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
241000606790 Haemophilus Species 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
241000712079 Measles morbillivirus Species 0.000 description 1
FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
241001631646 Papillomaviridae Species 0.000 description 1
208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
102100029251 Phagocytosis-stimulating peptide Human genes 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
241000710799 Rubella virus Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
108010008038 Synthetic Vaccines Proteins 0.000 description 1
208000000389 T-cell leukemia Diseases 0.000 description 1
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
108010084754 Tuftsin Proteins 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
241000710772 Yellow fever virus Species 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000013566 allergen Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001687 destabilization Effects 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 1
108700003601 dimethylglycine Proteins 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
150000002337 glycosamines Chemical class 0.000 description 1
230000036541 health Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
208000005252 hepatitis A Diseases 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000002502 liposome Substances 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
239000002609 medium Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229960005323 phenoxyethanol Drugs 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000768 polyamine Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
229940035670 tuftsin Drugs 0.000 description 1
IESDGNYHXIOKRW-LEOABGAYSA-N tuftsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-LEOABGAYSA-N 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1
229940051021 yellow-fever virus Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Virology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO920161A 1989-07-14 1992-01-13 Fremgangsmåte for fremstilling av en stabil vaksineblanding og fremgangsmåte for stabilisering av interleukin i en vaksineblanding NO301577B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US37974289A	1989-07-14	1989-07-14
PCT/US1990/003982 WO1991001143A1 (en)	1989-07-14	1990-07-16	Stable vaccine compositions containing interleukins

Publications (3)

Publication Number	Publication Date
NO920161D0 NO920161D0 (no)	1992-01-13
NO920161L NO920161L (no)	1992-03-05
NO301577B1 true NO301577B1 (no)	1997-11-17

Family

ID=23498494

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO920161A NO301577B1 (no)	1989-07-14	1992-01-13	Fremgangsmåte for fremstilling av en stabil vaksineblanding og fremgangsmåte for stabilisering av interleukin i en vaksineblanding

Country Status (12)

Country	Link
EP (1)	EP0482076B1 (da)
JP (2)	JP3485184B2 (da)
KR (1)	KR0177179B1 (da)
AT (1)	ATE121629T1 (da)
AU (1)	AU648509B2 (da)
CA (1)	CA2063587C (da)
DE (1)	DE69018990T2 (da)
DK (1)	DK0482076T3 (da)
ES (1)	ES2075900T3 (da)
FI (1)	FI104233B (da)
NO (1)	NO301577B1 (da)
WO (1)	WO1991001143A1 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1991006319A1 (en) *	1989-10-27	1991-05-16	Arch Development Corporation	Methods and compositions for promoting immunopotentiation
US6406696B1 (en)	1989-10-27	2002-06-18	Tolerance Therapeutics, Inc.	Methods of stimulating the immune system with anti-CD3 antibodies
GR1000881B (el) *	1990-08-06	1993-03-16	Praxis Biolog Inc	Σταθερες συνθεσεις εμβολιου που περιεχουν ιντερλευκινες.
CZ119993A3 (en) *	1990-12-19	1994-02-16	Schering Corp	The use of il-4 for increasing immune response to immunogens in vaccines
CA2109316A1 (en) *	1991-05-13	1992-11-14	Edward Abraham	Liposomal polysaccharide vaccines
DE4126983A1 (de)	1991-08-15	1993-02-18	Boehringer Mannheim Gmbh	Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
WO1994003202A1 (en) *	1992-08-10	1994-02-17	The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	Interleukin-4 stimulated t lymphocyte cell death
ZA936095B (en) *	1992-08-21	1994-03-14	Univ Melbourne	Cytokine applications.
US6491916B1 (en)	1994-06-01	2002-12-10	Tolerance Therapeutics, Inc.	Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
AU3541495A (en) *	1994-09-01	1996-03-22	Wisconsin Alumni Research Foundation	Therapeutic remodeling in aids
US6509313B1 (en) *	1996-02-28	2003-01-21	Cornell Research Foundation, Inc.	Stimulation of immune response with low doses of cytokines
ES2262181T3 (es) *	1996-05-31	2006-11-16	National University Of Ireland, Maynooth	Il-12 como adyuvante en la vacuna contra la especie bordetella pertussis.
TW586934B (en) *	1997-05-19	2004-05-11	Sumitomo Pharma	Immunopotentiating composition
US6270758B1 (en)	1998-10-08	2001-08-07	Duke University	Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
US6027731A (en) *	1998-11-17	2000-02-22	Wisconsin Alumni Research Foundation	Pertussis toxin induced lymphocytosis
IT1302534B1 (it)	1998-12-21	2000-09-05	Fidia Advanced Biopolymers Srl	Composizioni iniettabili, biocompatibili e biodegradabili comprendentialmeno un derivato dell'acido ialuronico, cellule condrogeniche, per
SK782002A3 (en) *	1999-07-21	2003-08-05	Lexigen Pharm Corp	FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU1813701A (en)	1999-12-03	2001-06-12	Celltech Chiroscience Limited	Interleukin-1 muteins useful as vaccine adjuvants
JP2009500457A (ja)	2005-07-11	2009-01-08	マクロジェニクス，インコーポレーテッド	毒性の低下した免疫抑制モノクローナル抗体を使用する自己免疫疾患の治療法
ES2374648T3 (es) *	2005-09-30	2012-02-20	Lipoxen Technologies Limited	Composiciones de vacunas liposómicas que comprenden un antígeno polisacárido y un adyuvante proteico.
EP2037961B1 (en)	2006-06-14	2015-11-11	MacroGenics, Inc.	Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
AU2008226974B2 (en) *	2007-03-09	2013-08-15	Merck Sharp & Dohme Llc	Papillomavirus vaccine compositions
ES2641375T3 (es) *	2012-11-02	2017-11-08	Cytuvax	Composición que comprende macroagregados de citoquinas
JOP20190242A1 (ar) *	2018-10-12	2020-04-12	Serum Institute Of India Pvt Ltd	تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
CN113365650A (zh)	2018-11-16	2021-09-07	新免疫技术有限公司	用il-7蛋白和免疫检查点抑制剂的组合***的方法
JP2023512456A (ja)	2020-01-13	2023-03-27	ネオイミューンテック，インコーポレイテッド	Ｉｌ－７タンパク質と二重特異性抗体の組み合わせで腫瘍を治療する方法
AU2021217373A1 (en)	2020-02-05	2022-08-04	Neoimmunetech, Inc.	Method of treating a solid tumor with a combination of an IL-7 protein and CAR-bearing immune cells
WO2022093718A1 (en)	2020-10-26	2022-05-05	Neoimmunetech, Inc.	Methods of inducing stem cell mobilization
KR20230104176A (ko)	2020-11-02	2023-07-07	네오이뮨텍, 인코퍼레이티드	코로나바이러스의 치료를 위한 인터류킨-7의 용도
CA3195594A1 (en)	2020-11-05	2022-05-12	Byung Ha Lee	Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
WO2023130081A1 (en)	2021-12-30	2023-07-06	Neoimmunetech, Inc.	Method of treating a tumor with a combination of il-7 protein and vegf antagonist
WO2024102722A1 (en)	2022-11-07	2024-05-16	Neoimmunetech, Inc.	Methods of treating a tumor with an unmethylated mgmt promoter

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2849632B2 (ja) *	1988-04-08	1999-01-20	社団法人北里研究所	ワクチン製剤
DE3818054C2 (de) *	1988-05-27	1994-02-17	Biotest Pharma Gmbh	Verwendung einer Kombination aus einem Antigen bzw. einer Vakzine und humanem Interleukin zur Behandlung der Non-Responsiveness gegenüber immunologischen Defektzuständen
JPH0236129A (ja) *	1988-07-22	1990-02-06	Ajinomoto Co Inc	ワクチン効果増強剤

1990
- 1990-07-16 KR KR1019920700086A patent/KR0177179B1/ko not_active IP Right Cessation
- 1990-07-16 AU AU60500/90A patent/AU648509B2/en not_active Ceased
- 1990-07-16 CA CA002063587A patent/CA2063587C/en not_active Expired - Fee Related
- 1990-07-16 JP JP51060090A patent/JP3485184B2/ja not_active Expired - Fee Related
- 1990-07-16 DK DK90911344.1T patent/DK0482076T3/da active
- 1990-07-16 DE DE69018990T patent/DE69018990T2/de not_active Expired - Fee Related
- 1990-07-16 EP EP90911344A patent/EP0482076B1/en not_active Expired - Lifetime
- 1990-07-16 WO PCT/US1990/003982 patent/WO1991001143A1/en active IP Right Grant
- 1990-07-16 ES ES90911344T patent/ES2075900T3/es not_active Expired - Lifetime
- 1990-07-16 AT AT90911344T patent/ATE121629T1/de not_active IP Right Cessation
1992
- 1992-01-13 NO NO920161A patent/NO301577B1/no unknown
- 1992-01-13 FI FI920132A patent/FI104233B/fi not_active IP Right Cessation
2003
- 2003-07-31 JP JP2003284148A patent/JP2004002463A/ja active Pending

Also Published As

Publication number	Publication date
CA2063587C (en)	2005-08-30
DE69018990D1 (de)	1995-06-01
DK0482076T3 (da)	1995-07-17
AU648509B2 (en)	1994-04-28
JPH04506663A (ja)	1992-11-19
JP2004002463A (ja)	2004-01-08
NO920161L (no)	1992-03-05
FI104233B1 (fi)	1999-12-15
AU6050090A (en)	1991-02-22
ES2075900T3 (es)	1995-10-16
ATE121629T1 (de)	1995-05-15
NO920161D0 (no)	1992-01-13
WO1991001143A1 (en)	1991-02-07
FI104233B (fi)	1999-12-15
EP0482076B1 (en)	1995-04-26
JP3485184B2 (ja)	2004-01-13
EP0482076A1 (en)	1992-04-29
DE69018990T2 (de)	1995-12-14
CA2063587A1 (en)	1991-01-15
KR920703103A (ko)	1992-12-17
FI920132A0 (fi)	1992-01-13
KR0177179B1 (ko)	1999-03-20

Publication	Publication Date	Title
NO301577B1 (no)	1997-11-17	Fremgangsmåte for fremstilling av en stabil vaksineblanding og fremgangsmåte for stabilisering av interleukin i en vaksineblanding
US7169391B2 (en)	2007-01-30	Vaccines
Nunberg et al.	1989	Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine.
Lin et al.	1995	Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases
US7374751B1 (en)	2008-05-20	QS-21 and IL-12 as an adjuvant combination
AU2001270031A1 (en)	2002-03-21	QS-21 and IL-12 as an adjuvant combination
IE914436A1 (en)	1992-07-01	Use of IL-4 to enhance immune response to immunogens in vaccines
AU2002225972B2 (en)	2006-06-29	Adjuvant combination formulations
NZ250555A (en)	1995-04-27	Vaccine with enhanced immunogenicity by inclusion of a cytokine
EP1490100B1 (en)	2011-12-28	Combined dna/protein vaccine compositions
WO1999040937A2 (en)	1999-08-19	Vaccines comprising interleukin-12 and respiratory syncytial viral antigens
MXPA00007881A (en)	2002-03-26	Vaccines comprising interleukin-12 and respiratory syncytial viral antigens